Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $276.6 million.

  • Pliant Therapeutics' Liabilities and Shareholders Equity fell 3793.54% to $276.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 3285.59%. This contributed to the annual value of $396.9 million for FY2024, which is 2249.42% down from last year.
  • Latest data reveals that Pliant Therapeutics reported Liabilities and Shareholders Equity of $276.6 million as of Q3 2025, which was down 3793.54% from $299.8 million recorded in Q2 2025.
  • Pliant Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $597.9 million during Q1 2023, with a 5-year trough of $184.6 million in Q2 2022.
  • For the 5-year period, Pliant Therapeutics' Liabilities and Shareholders Equity averaged around $373.2 million, with its median value being $350.6 million (2022).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 21139.32% in 2023, then plummeted by 3801.83% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Liabilities and Shareholders Equity stood at $221.2 million in 2021, then surged by 58.49% to $350.6 million in 2022, then skyrocketed by 46.07% to $512.2 million in 2023, then dropped by 22.49% to $396.9 million in 2024, then tumbled by 30.32% to $276.6 million in 2025.
  • Its last three reported values are $276.6 million in Q3 2025, $299.8 million for Q2 2025, and $344.8 million during Q1 2025.